Borneol-Edaravone mitigates ischemic brain injury in MCAO rats.

BACKGROUND

Borneol-Edaravone, a derivative combining borneol and Edaravone, was evaluated for its neuroprotective and anti-inflammatory effects in a rat model of middle cerebral artery occlusion (MCAO), and its efficacy was compared with Edaravone alone.

METHODS

Borneol-Edaravone was administered intraperitoneally (IP) twice daily, starting at 6 h post-stroke induction and continuing for 7 days. Post-stroke outcomes, including sensorimotor function, neuroprotection, and inflammation markers were assessed.

RESULTS

As an anti-inflammatory agent(inhibited astrocyte and microglial overactivation, and reduced oxidative/nitrative stress markers (3-NT, 4-HNE), and its effectiveness in improving sensorimotor deficits and reduced cerebral infarct volume in the MCAO, Borneol-Edaravone demonstrated superior neuroprotection to Edaravone.

CONCLUSION

These findings suggest that Borneol-Edaravone exerts both neuroprotective and anti-inflammatory effects and may offer enhanced protection with an extended therapeutic window from 4.5 to 6 h against cerebral ischemia-reperfusion injury compared to Edaravone.